UK’s NICE Under Fire For New HTA Fees
Executive Summary
Fees for appraisals that the health technology assessment body, NICE, will introduce in April could adversely impact companies with medicines for smaller indications, despite a bigger fee reduction for some manufacturers.
You may also be interested in...
England: HTA Body’s Income Hit By COVID-19
England’s health technology assessment body NICE did not recover costs for technology appraisals through fees thanks to the COVID-19 pandemic.
UK: NICE Fees Plan Would Cost Life Sciences Industry £10m Each Year
England’s department of health is again consulting on plans to allow health technology appraisal body NICE to charge companies for conducting appraisals.
Lack Of Industry Involvement In EU HTA Scoping Process Exacerbates ‘Unworkable’ Timelines
Scientific advice could help companies make up for the lack of involvement in scoping, but slots are in short supply.